EUVIMEDEUVIMED entdecken
Open Access

Thrombopoietin Receptor Agonists for Thrombocytopenia in Pediatric Hematologic Malignancies

Amanda E Marinoff iD, Allyson Thrall, Kathryn Aaronson, Benjamin S Braun, Maria Castellanos, Julia Chu, Michelle Hermiston, Benjamin J Huang, Anya Levinson, Erica Southworth, Beth Apsel Winger iD, Adam Olshen und 1 weitere

Pediatric Blood & Cancer · 2025

DOI: 10.1002/pbc.31528 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2025. Verfasst von Amanda E Marinoff und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Benioff Children's Hospitals, University of California, San Francisco, California, USA. Hauptthemen laut MEDLINE: Receptors, Thrombopoietin, Thrombocytopenia, Hematologic Neoplasms, Thrombopoietin. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Thrombopoietin receptor agonists (TPO‐RAs) have demonstrated efficacy in treating clinically significant thrombocytopenia, including chemotherapy‐induced thrombocytopenia in adults. However, data regarding their safety and efficacy in pediatric, adolescents, and young adult (AYA) patients with hematologic malignancies are limited.

Methods

We retrospectively identified 15 pediatric and AYA patients aged 25 years or younger with hematologic malignancies treated with a TPO‐RA at UCSF Benioff Children's Hospitals between 2015 and 2023. Platelet counts and transfusion requirements were compared before and after TPO‐RA therapy.

Results

The median age at TPO‐RA initiation was 16 years (range: 7–25 years). Nine patients (60%) had a history of bleeding or comorbidity that predisposed to severe bleeding risk. Eleven patients received romiplostim and four patients received eltrombopag. The median platelet count significantly increased from 24 × 10 9 /L at baseline to 54 × 10 9 /L after 3 weeks of any TPO‐RA therapy ( p = 0.029). Monthly platelet transfusion requirements significantly decreased from a median of 15 to two units after TPO‐RA therapy ( p = 0.007). Fourteen of the 15 patients (93%) achieved a sustained platelet count >50,000/µL within 8 weeks, with a median time to response of 3 weeks. No TPO‐RA‐related adverse events were observed.

Conclusion

TPO‐RAs were effective in managing refractory thrombocytopenia in pediatric and young adult patients being treated for hematologic malignancies, with a favorable safety profile, even among patients with multiple comorbidities. These findings warrant further investigation through prospective clinical trials to confirm efficacy and establish clinical guidelines for this population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, ThrombopoietinThrombocytopeniaHematologic NeoplasmsThrombopoietinHydrazinesRecombinant Fusion ProteinsPyrazolesBenzoatesReceptors, FcHumansAdolescentChildFemaleMaleRetrospective StudiesYoung AdultAdultFollow-Up StudiesPrognosisPlatelet Count

Stichwörter der Autor:innen

adolescenteltrombopaghematologic malignanciesleukemiapediatricromiplostimthrombopoietin receptor agonistyoung adults

Substanzen

Receptors, ThrombopoietinThrombopoietinromiplostimeltrombopagHydrazinesRecombinant Fusion ProteinsPyrazolesBenzoatesReceptors, Fc

Autor:innen und Institutionen

  • Department of Pediatrics, Benioff Children's Hospitals, University of California, San Francisco, California, USA.
  • VinUniversity (Trường Đại học VinUni), Vinhomes Ocean Park, Gia Lâm, Vietnam.
  • Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA.

ORCID-Profile: Amanda E Marinoff, Beth Apsel Winger, Elliot Stieglitz

Förderung

  • NCI NIH HHS

Zitieren

APA

Marinoff, A. E., Thrall, A., Aaronson, K., Braun, B. S., Castellanos, M., Chu, J., Hermiston, M., Huang, B. J., Levinson, A., Southworth, E., Winger, B. A., Olshen, A., & Stieglitz, E. (2025). Thrombopoietin Receptor Agonists for Thrombocytopenia in Pediatric Hematologic Malignancies. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31528

Vancouver

Marinoff AE, Thrall A, Aaronson K, Braun BS, Castellanos M, Chu J, et al. Thrombopoietin Receptor Agonists for Thrombocytopenia in Pediatric Hematologic Malignancies. Pediatric Blood & Cancer. 2025. doi:10.1002/pbc.31528

BibTeX
@article{Marinoff2025,
  author = {Marinoff, Amanda E and Thrall, Allyson and Aaronson, Kathryn and Braun, Benjamin S and Castellanos, Maria and Chu, Julia and Hermiston, Michelle and Huang, Benjamin J and Levinson, Anya and Southworth, Erica and Winger, Beth Apsel and Olshen, Adam and Stieglitz, Elliot},
  title = {Thrombopoietin Receptor Agonists for Thrombocytopenia in Pediatric Hematologic Malignancies},
  journal = {Pediatric Blood & Cancer},
  year = {2025},
  doi = {10.1002/pbc.31528}
}
Kostenlos starten →